title: Different susceptibility to neurodegeneration of dorsal and ventral hippocampal dentate gyrus: a study with transgenic mice overexpressing GSK3β.
abstract: Dorsal hippocampal regions are involved in memory and learning processes, while ventral areas are related to emotional and anxiety processes. Hippocampal dependent memory and behaviour alterations do not always come out in neurodegenerative diseases at the same time. In this study we have tested the hypothesis that dorsal and ventral dentate gyrus (DG) regions respond in a different manner to increased glycogen synthase kinase-3β (GSK3β) levels in GSK3β transgenic mice, a genetic model of neurodegeneration. Reactive astrocytosis indicate tissue stress in dorsal DG, while ventral area does not show that marker. These changes occurred with a significant reduction of total cell number and with a significantly higher level of cell death in dorsal area than in ventral one as measured by fractin-positive cells. Biochemistry analysis showed higher levels of phosphorylated GSK3β in those residues that inactivate the enzyme in hippocampal ventral areas compared with dorsal area suggesting that the observed susceptibility is in part due to different GSK3 regulation. Previous studies carried out with this animal model had demonstrated impairment in Morris Water Maze and Object recognition tests point out to dorsal hippocampal atrophy. Here, we show that two tests used to evaluate emotional status, the light-dark box and the novelty suppressed feeding test, suggest that GSK3β mice do not show any anxiety-related disorder. Thus, our results demonstrate that in vivo overexpression of GSK3β results in dorsal but not ventral hippocampal DG neurodegeneration and suggest that both areas do not behave in a similar manner in neurodegenerative processes.
authors.affiliation: Centro de Biología Molecular Severo Ochoa, CSIC/UAM, Universidad Autónoma de Madrid, Cantoblanco, Madrid, Spain.
authors.forename: Almudena
authors.initials: A
authors.lastname: Fuster-Matanzo
authors.forename: María
authors.initials: M
authors.lastname: Llorens-Martín
authors.forename: Elena Gómez
authors.initials: EG
authors.lastname: de Barreda
authors.forename: Jesús
authors.initials: J
authors.lastname: Ávila
authors.forename: Félix
authors.initials: F
authors.lastname: Hernández
mesh_terms: D000818:Animals; D001522:Behavior, Animal; D015153:Blotting, Western; D003624:Darkness; D018891:Dentate Gyrus / Q000473:pathology*; D038362:Glycogen Synthase Kinase 3 / Q000378:metabolism*; D000071679:Glycogen Synthase Kinase 3 beta; D008027:Light; D051379:Mice; D008822:Mice, Transgenic; D010766:Phosphorylation
chemical_list: D000071679:Glycogen Synthase Kinase 3 beta; C000605507:Gsk3b protein, mouse; D038362:Glycogen Synthase Kinase 3
references.citation: Neuron. 2010 Jan 14;65(1):7-19
references.pmid: 20152109
references.citation: Proc Natl Acad Sci U S A. 1996 Aug 6;93(16):8455-9
references.pmid: 8710892
references.citation: EMBO J. 2001 Jan 15;20(1-2):27-39
references.pmid: 11226152
references.citation: J Neurochem. 2000 Apr;74(4):1587-95
references.pmid: 10737616
references.citation: Trends Mol Med. 2002 Mar;8(3):126-32
references.pmid: 11879773
references.citation: Prog Neurobiol. 2006 Jul;79(4):173-89
references.pmid: 16935409
references.citation: J Neurosci. 2006 May 10;26(19):5083-90
references.pmid: 16687499
references.citation: J Neurochem. 2006 Dec;99(6):1445-55
references.pmid: 17059563
references.citation: Prog Neurobiol. 2001 Nov;65(4):391-426
references.pmid: 11527574
references.citation: J Neurosci. 1996 Jul 15;16(14):4491-500
references.pmid: 8699259
references.citation: J Neurosci. 2000 Apr 1;20(7):2567-74
references.pmid: 10729337
references.citation: Neuroscience. 1996 Aug;73(4):1145-57
references.pmid: 8809831
references.citation: Physiol Rev. 2004 Apr;84(2):361-84
references.pmid: 15044677
references.citation: Eur J Pharmacol. 2010 Jan 10;626(1):49-56
references.pmid: 19836379
references.citation: J Neurosci Res. 1994 Dec 15;39(6):669-73
references.pmid: 7534834
references.citation: Eur J Neurosci. 2007 Jan;25(1):81-6
references.pmid: 17241269
references.citation: Proc Natl Acad Sci U S A. 1999 Mar 30;96(7):4034-9
references.pmid: 10097158
references.citation: J Biol Chem. 2002 Sep 13;277(37):33791-8
references.pmid: 12097329
references.citation: EMBO J. 1990 Aug;9(8):2431-8
references.pmid: 2164470
references.citation: Nat Rev Drug Discov. 2004 Jun;3(6):479-87
references.pmid: 15173837
references.citation: J Biol Chem. 1998 Aug 7;273(32):19929-32
references.pmid: 9685326
references.citation: J Neuropathol Exp Neurol. 1999 Sep;58(9):1010-9
references.pmid: 10499443
references.citation: J Neurosci. 2001 Jan 1;21(1):194-200
references.pmid: 11150336
references.citation: Trends Biochem Sci. 2004 Feb;29(2):95-102
references.pmid: 15102436
references.citation: Hippocampus. 2009 Apr;19(4):360-70
references.pmid: 19004012
references.citation: Curr Pharm Des. 2010;16(25):2790-8
references.pmid: 20698823
references.citation: Neurobiol Aging. 2006 Sep;27(9):1258-68
references.pmid: 16054268
references.citation: Eur Neuropsychopharmacol. 2002 Feb;12(1):13-25
references.pmid: 11788236
references.citation: FEBS Lett. 1997 Jul 14;411(2-3):183-8
references.pmid: 9271202
references.citation: Proc Natl Acad Sci U S A. 1991 Jul 1;88(13):5837-41
references.pmid: 1712107
references.citation: Hippocampus. 2006;16(5):480-90
references.pmid: 16596582
references.citation: Prog Brain Res. 2007;163:723-40
references.pmid: 17765747
references.citation: J Neurochem. 2002 Dec;83(6):1529-33
references.pmid: 12472906